awmsg logo



adalimumab (Humira®)


Reference No. 6

Publication date:
02/08/2006


Appraisal information

adalimumab (Humira®) 40 mg solution for injection


Company: AbbVie Ltd
BNF category: Musculoskeletal and joint diseases
NMG meeting date: Not scheduled
AWMSG meeting date: 07/06/2006
   
   
Submission Type: Full Submission
Status: Superseded
Advice No: Not available
Ministerial ratification: 28/07/2006

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA125) NICE GUIDANCE ISSUED AUGUST 2007 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Adalimumab (Humira®) should be available for use within NHS Wales for the treatment of psoriatic arthritis (PsA) in accordance with the licensed indication and supervised by specialist physicans experienced in the diagnosis and treatment of PsA subject to the following restriction: Adalimumab (Humira®) is used in accordance with the current British Society of Rheumatology Guidelines for anti-TNF-alpha therapy in adults with psoriatic arthritis.
Final Appraisal Recommendation (FAR)
Download